Plasma apolipoprotein C-III transport in centrally obese men: Associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 557-564

  Chan, Dick C ^a   Nguyen, Minh N ^a   Watts, Gerald F ^a   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN METABOLISM;

EID: 39049083945     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2676     Document Type: Article

References (38)

1. Ginsberg HN 2000 Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458
2. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G 2003 Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168:81-89
3. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E 2000 VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102:1886-1892
4. Brown VW, Baginsky ML 1972 Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46:375-382
5. Sehayek E, Eisenberg S 1991 Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266:18259-18267
6. Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, Mamer O, Davignon J 2004 Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis 177:137-145
7. Chan DC, Watts GF, Nguyen MN, Barrett PHR 2006 Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol 26:590-596
8. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G 2004 Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89:3949-3955
9. Le NA, Gibson JC, Ginsberg HN 1988 Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res 29:669-677
10. Glangeaud MC, Eisenberg S, Olivecrona T 1976 Very low density lipoprotein: dissociation of apolipoprotein C during lipoprotein lipase induced lipolysis. Biochim Biophys Acta 486:23-35
11. Wu AL, Windmueller HG 1979 Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J Biol Chem 254:7316-7322
12. Huff MW, Fidge NH, Nestel PJ, Billington T, Watson B 1981 Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res 22:1235-1246
13. Eisenberg S, Bilheimer DW, Levy RI 1972 The metabolism of very low density lipoprotein proteins: II. Studies on the transfer of apoproteins between plasma lipoproteins. Biochim Biophys Acta 280:94-104
14. Malmendier CL, Lontie JF, Grutman GA, Delcroix C 1988 Metabolism of apolipoprotein C-III in normolipemic human subjects. Atherosclerosis 69:51-59
15. Bukberg PR, Le NA, Ginsberg HN, Gibson JC, Rubinstein A, Brown WV 1985 Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res 26:1047-1057
16. Tornoci L, Scheraldi CA, Li X, Ide H, Goldberg IJ, Le NA 1993 Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res 34:1793-1803
17. Le NA, Bukberg PR, Ginsberg HN, Gibson JC, Brown VW 1996 Direct determination of apolipoprotein C-III specific activity using immunoaffinity chromatography. Methods Enzymol 129:457-469
18. Cohn JS, Batal R, Tremblay M, Jacques H, Veilleux L, Rodriguez C, Mamer O, Davignon J 2003 Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J Lipid Res 44:1976-1983
19. Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS 2000 Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 41:706-718
20. Nguyen MN, Chan DC, Dwyer KP, Bolitho P, Watts GF, Barrett PHR 2006 Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. J Lipid Res 47:1274-1280
21. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PHR 2002 Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51:1041-1046
22. Chan DC, Watts GF, Barrett PHR, Beilin LJ, Redgrave TG, Mori TA 2002 Regulatory Effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51:2377-2386
23. Brites FD, Bonavita CD, Cloes M, Yael MJ, Fruchart JC, Castro GR, Wikinski RW 1998 VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. Clin Chim Acta 269:107-124
24. Watts GF, Barrett PHR, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG 2003 Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52: 803-811
25. Dwyer KP, Barrett PHR, Chan DC, Foo JI, Watts GF, Croft KD 2002 Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J Lipid Res 43:344-349
26. Fidge NH, Nestel PJ 1986 Metabolism of apolipoprotein C. Methods Enzymol 129:443-457
27. Mauger JF, Couture P, Bergeron N, Lamarche B 2006 Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res 47:1212-1218
28. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PHR 1999 Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 84:2854-2861
29. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L 1989 Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients: effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 77:139-149
30. Sundaram M, Links P, Khalil MB, Zhong S, Yao Z 2007 New insights into the roles of apolipoprotein C-III in stimulating the production of hepatic VLDL. Arterioscler Thromb Vasc Biol 27:e62
31. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF 1999 Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 103:1191-1199
32. Rashid S, Barrett PHR, Uffelman KD, Watanabe T, Adeli K, Lewis GF 2002 Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 22:483-487
33. Watts GF, Riches FM, Humphries SE, Talmud PJ, van Bockxmeer FM 2000 Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 41:481-488
34. Chan DC, Watts GF, Barrett PHR, Whitfield AJ, van Bockxmeer FM 2004 ATP-binding cassette transporter G8 gene as a determinant of apolipoprotein B-100 kinetics in overweight men. Arterioscler Thromb Vasc Biol 24:2188-2191
35. Watts GF, Moroz P, Barrett PH 2000 Kinetics of very-low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: pooled analysis of stable-isotope studies. Metabolism 49:1204-1210
36. Mooradian AD, Haas MJ, Wong NCW 2006 The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 27:2-16
37. Ng TW, Watts GF, Barrett PHR, Rye KA, Chan DC 2007 Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 30:2945-2950
38. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bendadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN 2006 Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115:1323-1332